CMT Asset Management’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q4
Sell
-193,400
Closed -$12.3M 28
2017
Q3
$12.3M Sell
193,400
-66,400
-26% -$3.88M 0.59% 57
2017
Q2
$14.5M Buy
259,800
+25,800
+11% +$1.4M 0.96% 35
2017
Q1
$12.7M Buy
234,000
+26,900
+13% +$1.48M 1.07% 28
2016
Q4
$12.1M Buy
207,100
+63,900
+45% +$3.49M 0.57% 55
2016
Q3
$7.72M Buy
143,200
+132,600
+1,251% +$8.52M 0.35% 72
2016
Q2
$780K Sell
10,600
-80,000
-88% -$5.65M 0.04% 155
2016
Q1
$5.79M Sell
90,600
-10,000
-10% -$631K 0.39% 76
2015
Q4
$6.92M Sell
100,600
-16,300
-14% -$1.08M 0.35% 67
2015
Q3
$6.92M Buy
116,900
+41,900
+56% +$2.66M 0.39% 73
2015
Q2
$4.99M Buy
75,000
+25,000
+50% +$1.65M 0.31% 85
2015
Q1
$3.23M Sell
50,000
-104,300
-68% -$6.53M 0.23% 90
2014
Q4
$9.11M Buy
154,300
+9,000
+6% +$508K 0.54% 58
2014
Q3
$7.44M Buy
145,300
+20,100
+16% +$1M 0.39% 68
2014
Q2
$6.07M Sell
125,200
-21,300
-15% -$1.05M 0.33% 79
2014
Q1
$7.61M Buy
146,500
+14,900
+11% +$793K 0.96% 31
2013
Q4
$7M Sell
131,600
-21,700
-14% -$1.11M 0.35% 75
2013
Q3
$7.09M Buy
153,300
+22,700
+17% +$996K 0.36% 72
2013
Q2
$5.84M Buy
+130,600
New +$5.67M 0.29% 77

Other funds holding BMY

CMT Asset Management's BMY Position: Q3 2017 in Review

CMT Asset Management sold out of Bristol-Myers Squibb (BMY) in Q3 2017, closing a stake of 13,000 shares — an estimated $759K sold.

CMT Asset Management first reported a position in BMY in Q4 2013 and held it in 7 quarters. The position peaked at $5.35M in Q4 2016. 1,641 funds tracked by Wall St. Rank hold BMY as of Q3 2017.

  • CMT Asset Management reported no remaining Bristol-Myers Squibb position as of Q3 2017 after selling out during the quarter.
  • CMT Asset Management sold 13,000 Bristol-Myers Squibb shares in Q3 2017, an estimated $759K.
  • CMT Asset Management first reported a position in Bristol-Myers Squibb in Q4 2013 and held it in 7 quarters.
  • CMT Asset Management's Bristol-Myers Squibb position peaked at $5.35M in Q4 2016.
  • 1,641 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2017.

Based on CMT Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.